

Abacavir

683

10-Sep-2018

● INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs

▶ BY MOUTH

▶ Adult: 600 mg daily in 1–2 divided doses

- **CAUTIONS** HIV load greater than 100 000 copies/mL · patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)

● **INTERACTIONS** → Appendix 1: abacavir

● SIDE-EFFECTS

- ▶ **Common or very common** Appetite decreased · fever · lethargy
 - ▶ **Rare or very rare** Severe cutaneous adverse reactions (SCARs)
 - ▶ **Frequency not known** Hypersensitivity · weight increased
- SIDE-EFFECTS, FURTHER INFORMATION** Life-threatening hypersensitivity reactions have been reported—characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis. Laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time. Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction).

- **ALLERGY AND CROSS-SENSITIVITY** Caution—increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.

● **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild impairment; consider avoiding in moderate to severe impairment (no information available).

● **RENAL IMPAIRMENT** Manufacturer advises avoid in end-stage renal disease.

● **PRE-TREATMENT SCREENING** Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known.

● **MONITORING REQUIREMENTS** Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.

● **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana, or strawberry.

● **PATIENT AND CARER ADVICE** Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment. Patients should be provided with an alert card and advised to keep it with them at all times.

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Oral solution

EXCIPIENTS: May contain Propylene glycol

▶ **Ziagen** (ViiV Healthcare UK Ltd)

Abacavir (as Abacavir sulfate) 20 mg per 1 ml Ziagen 20mg/ml oral solution sugar-free | 240 ml [PoM] £55.72

Tablet

▶ **Abacavir (Non-proprietary)**

Abacavir (as Abacavir sulfate) 300 mg Abacavir 300mg tablets | 60 tablet [PoM] £177.60–£177.61

▶ **Ziagen** (ViiV Healthcare UK Ltd)

Abacavir (as Abacavir sulfate) 300 mg Ziagen 300mg tablets | 60 tablet [PoM] £208.95

Abacavir with dolutegravir and lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir above, lamivudine p. 689, dolutegravir p. 678.

● INDICATIONS AND DOSE

HIV infection

▶ BY MOUTH

▶ Adult (body-weight 40 kg and above): 1 tablet once daily

● **INTERACTIONS** → Appendix 1: abacavir · dolutegravir · lamivudine

● **RENAL IMPAIRMENT** Avoid *Triumeq*[®] if eGFR less than 50 mL/minute/1.73 m² (consult product literature).

● PATIENT AND CARER ADVICE

Missed doses If a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

▶ **Triumeq** (ViiV Healthcare UK Ltd)

Dolutegravir (as Dolutegravir sodium) 50 mg, Lamivudine 300 mg, Abacavir (as Abacavir sulfate) 600 mg Triumeq 50mg/600mg/300mg tablets | 30 tablet [PoM] £798.16

Abacavir with lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir above, lamivudine p. 689.

● INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals

▶ BY MOUTH

▶ Adult (body-weight 40 kg and above): 1 tablet once daily

● **INTERACTIONS** → Appendix 1: abacavir · lamivudine

● **RENAL IMPAIRMENT** Avoid *Kivexa*[®] if eGFR less than 50 mL/minute/1.73 m² (consult product literature).

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

▶ **Abacavir with lamivudine (Non-proprietary)**

Lamivudine 300 mg, Abacavir 600 mg Abacavir 600mg / Lamivudine 300mg tablets | 30 tablet [PoM] £352.25 DT = £190.00 | 30 tablet [PoM] £224.56 DT = £190.00 (Hospital only)

▶ **Kivexa** (ViiV Healthcare UK Ltd)

Lamivudine 300 mg, Abacavir 600 mg Kivexa 600mg/300mg tablets | 30 tablet [PoM] £352.25 DT = £190.00